This project takes a closer look at the financial performance of Aurobindo Pharma, using different financial tools and techniques. We dive into aspects like the company's liquidity, profitability, solvency, and efficiency over four years (2021–2024), by examining key financial statements such as the balance sheet, income statement, and cash flow statement. For the study, several methods include ratio analysis, common size analysis, comparative analysis, and trend analysis to evaluate financial stability and growth patterns. The results provide insights into the company’s financial health, pointing out strengths, weaknesses, and areas where improvements can be made. This study acts as a useful resource for investors, management, and stakeholders to help them make knowledgeable financial decisions.
Jetzt kaufen
- Arbeit zitieren
- M. Arul Jothi (Autor:in), 2024, Decoding Aurobindo Pharma’s Financial Health. A Four-Year Analytical Study (2021–2024), München, GRIN Verlag, https://www.grin.com/document/1580262
